Athersys (NASDAQ:ATHX)‘s stock had its “buy” rating reiterated by equities research analysts at Maxim Group in a research note issued to investors on Tuesday. They currently have a $6.00 price target on the biopharmaceutical company’s stock. Maxim Group’s target price would indicate a potential upside of 198.51% from the company’s previous close.
The analysts wrote, “Summary Athersys issued a press release this morning ahead of their scheduled earnings release and conference call tonight. News is that the company will significantly expand their existing development and commercialization collaboration with partner Healios (6927JP – ¥998 – NR). Healios will make a ~$21M equity investment at $1.76 per share, a premium to Athersys current share price of $1.56. Specifics mentioned:.””
Separately, ValuEngine cut Athersys from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st.
Athersys (NASDAQ:ATHX) last issued its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.04). Athersys had a negative net margin of 746.04% and a negative return on equity of 113.63%. The firm had revenue of $1.17 million during the quarter, compared to analysts’ expectations of $0.42 million. During the same quarter in the prior year, the firm posted ($0.10) EPS. Athersys’s quarterly revenue was up 19.0% compared to the same quarter last year. equities analysts anticipate that Athersys will post -0.25 EPS for the current fiscal year.
In other news, COO William Lehmann, Jr. sold 14,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $1.80, for a total value of $25,200.00. Following the transaction, the chief operating officer now owns 503,712 shares of the company’s stock, valued at $906,681.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders sold 29,000 shares of company stock worth $51,075. Corporate insiders own 9.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. NEXT Financial Group Inc increased its stake in Athersys by 31.6% during the third quarter. NEXT Financial Group Inc now owns 128,950 shares of the biopharmaceutical company’s stock worth $280,000 after acquiring an additional 31,000 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Athersys by 11.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 318,038 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 33,498 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Athersys by 35.3% in the 3rd quarter. Wells Fargo & Company MN now owns 167,176 shares of the biopharmaceutical company’s stock worth $345,000 after acquiring an additional 43,600 shares during the last quarter. Perkins Capital Management Inc. grew its holdings in shares of Athersys by 17.7% in the 4th quarter. Perkins Capital Management Inc. now owns 363,375 shares of the biopharmaceutical company’s stock worth $658,000 after acquiring an additional 54,650 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Athersys in the 4th quarter worth $108,000. 19.66% of the stock is currently owned by institutional investors and hedge funds.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.